MX2020011301A - Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares. - Google Patents
Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares.Info
- Publication number
- MX2020011301A MX2020011301A MX2020011301A MX2020011301A MX2020011301A MX 2020011301 A MX2020011301 A MX 2020011301A MX 2020011301 A MX2020011301 A MX 2020011301A MX 2020011301 A MX2020011301 A MX 2020011301A MX 2020011301 A MX2020011301 A MX 2020011301A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- ocular conditions
- pilocarpine hydrochloride
- methods
- ocular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Abstract
En la presente invención se describen métodos y composiciones para el tratamiento de afecciones oculares y para la mejora de los parámetros de la visión usando formulaciones oftálmicas de pilocarpina farmacéuticamente aceptables. Un ejemplo no limitativo de una afección ocular que puede ser tratada con los métodos y composiciones descritos en la presente invención es la presbicia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662144P | 2018-04-24 | 2018-04-24 | |
US201862780117P | 2018-12-14 | 2018-12-14 | |
US201962790957P | 2019-01-10 | 2019-01-10 | |
PCT/US2019/028917 WO2019209955A2 (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011301A true MX2020011301A (es) | 2021-01-29 |
Family
ID=66821312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011301A MX2020011301A (es) | 2018-04-24 | 2019-04-24 | Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares. |
Country Status (24)
Country | Link |
---|---|
US (3) | US10610518B2 (es) |
EP (2) | EP4066830A1 (es) |
JP (2) | JP6946575B2 (es) |
KR (2) | KR20210005134A (es) |
CN (1) | CN112272558A (es) |
AU (3) | AU2019261598B9 (es) |
BR (1) | BR112020021845A2 (es) |
CA (2) | CA3074618C (es) |
CL (1) | CL2020002734A1 (es) |
CO (1) | CO2020014563A2 (es) |
DK (1) | DK3681500T3 (es) |
ES (1) | ES2920803T3 (es) |
HR (1) | HRP20220762T1 (es) |
HU (1) | HUE058931T2 (es) |
IL (1) | IL278178A (es) |
LT (1) | LT3681500T (es) |
MX (1) | MX2020011301A (es) |
PH (1) | PH12020551766A1 (es) |
PL (1) | PL3681500T3 (es) |
PT (1) | PT3681500T (es) |
RS (1) | RS63360B1 (es) |
SG (1) | SG11202010472XA (es) |
SI (1) | SI3681500T1 (es) |
WO (1) | WO2019209955A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI822690B (zh) | 2017-07-20 | 2023-11-21 | 中國大陸商盛元醫藥廣州有限公司 | 用於治療近視之組合物及方法 |
MX2021004708A (es) | 2018-10-26 | 2021-11-03 | Ocuphire Pharma Inc | Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares. |
WO2022055796A1 (en) * | 2020-09-11 | 2022-03-17 | Intratus-Nevada, Inc. | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity |
JP2024505517A (ja) * | 2021-01-28 | 2024-02-06 | グラウコス コーポレイション | 製剤 |
WO2022232205A1 (en) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | A method of reducing brow ache |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
CN116350790A (zh) * | 2021-12-28 | 2023-06-30 | 沈阳兴齐眼药股份有限公司 | 组合物及其在制备用于治疗老花眼的药物中的用途 |
US11857538B2 (en) | 2022-01-14 | 2024-01-02 | Somerset Therapeutics, Llc | Stable pilocarpine formulations with modified buffer characteristics and related methods |
US20230248699A1 (en) | 2022-02-09 | 2023-08-10 | Somerset Therapeutics, Llc | Formulations of pilocarpine and brimonidine compounds and related methods |
WO2023205695A1 (en) | 2022-04-21 | 2023-10-26 | Glaukos Corporation | Ophthalmic topical cream compositions |
US20230372303A1 (en) | 2022-05-18 | 2023-11-23 | Glaukos Corporation | Applications of zwitterions in ophthalmic topical cream compositions and preparations |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
IL92351A (en) | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt |
US5122522A (en) | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
US5055467A (en) | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
US5776916A (en) | 1990-07-10 | 1998-07-07 | Gramer; Eugen | Medicament for reducing the intraocular pressure |
CA2064160C (en) | 1991-03-27 | 1998-08-11 | Paul J. T. Missel | Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
WO1994001096A1 (en) | 1992-07-02 | 1994-01-20 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
SE512871C2 (sv) | 1992-08-20 | 2000-05-29 | Santen Oy | Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension |
AU5599594A (en) * | 1992-11-16 | 1994-06-08 | Ciba-Geigy Ag | Polyvinyl alcohol/borate ophthalmic drug delivery system |
US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
US5574518A (en) | 1995-01-10 | 1996-11-12 | Les Laboratoires Opti-Centre Inc. | System incorporation two different sphero-non-spherical contact lenses for correcting presbytia |
US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
US6164282A (en) * | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
CH693625A5 (it) | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
IT1306135B1 (it) | 1999-04-26 | 2001-05-30 | Farmigea Spa | Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto. |
AU7581000A (en) | 1999-09-16 | 2001-04-17 | Gerald D. Horn | A method for optimizing pupil size using alpha antagonist |
US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
US6572849B2 (en) | 2000-09-20 | 2003-06-03 | Lee Shahinian, Jr. | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications |
US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
ITMI20010708A1 (it) | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter |
US20030139737A1 (en) | 2002-01-24 | 2003-07-24 | J.T. Lin | Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift |
CN103143022A (zh) | 2002-07-30 | 2013-06-12 | 奥默罗斯公司 | 眼科冲洗液及方法 |
US20070211212A1 (en) | 2002-09-26 | 2007-09-13 | Percy Bennwik | Eye state sensor |
US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
US20040078009A1 (en) | 2002-10-17 | 2004-04-22 | Lin J. T. | Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means |
US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
US20040137068A1 (en) | 2002-12-20 | 2004-07-15 | Rajiv Bhushan | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye |
CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
US20070053964A1 (en) | 2004-05-21 | 2007-03-08 | Akiharu Isowaki | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
US20050279369A1 (en) | 2004-06-21 | 2005-12-22 | Lin J T | Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation |
EP1827330A1 (en) | 2004-10-22 | 2007-09-05 | Acufocus | System and method for aligning an optic with an axis of an eye |
RU2435610C2 (ru) | 2005-09-02 | 2011-12-10 | Теравида, Инк. | Терапия для лечения заболевания |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
MX2009000385A (es) | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
DK1938839T3 (da) | 2006-12-18 | 2009-11-30 | Jorge Luis Benozzi | Oftalmiske sammensætninger af parasympatiske stimulanter og anti-inflammatoriske midler til anvendelse i behandlingen af presbyopi |
EP2195033A1 (en) | 2007-10-08 | 2010-06-16 | Fovea Pharmaceuticals SA | Aqueous ophthalmic formulations |
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
AU2015202175A1 (en) | 2007-12-15 | 2015-05-14 | Anant Sharma | Optical correction |
WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US20100298335A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
TW201109325A (en) | 2009-07-30 | 2011-03-16 | Wakamoto Pharma Co Ltd | Aqueous composition for eye drops |
AR081049A1 (es) | 2010-08-17 | 2012-06-06 | Gonzalez Santos Alejandro Raul | Medicamento oftalmico para el tratamiento de la hipermetropia |
ES2672238T3 (es) * | 2011-01-26 | 2018-06-13 | Allergan, Inc. | Composición androgénica para el tratamiento de una afección oftálmica |
DK2758047T3 (en) | 2011-09-20 | 2019-04-01 | Allergan Inc | COMPOSITIONS AND PROCEDURES FOR TREATING PRESBYOPY, MILD HYPEROPY AND IRREGULAR ASTIGMATISM |
RU2014118642A (ru) | 2011-10-12 | 2015-11-20 | Асцендис Фарма Офтальмолоджи Дивижн А/С | Предотвращение и лечение глазных нарушений |
RU2014129268A (ru) | 2011-12-16 | 2016-02-10 | Аллерган, Инк. | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля |
EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
PT2950648T (pt) | 2013-02-01 | 2020-01-06 | Ocuphire Pharma Inc | Soluções oftálmicas aquosas de fentolamina e usos médicos |
AU2014212275B2 (en) | 2013-02-01 | 2018-09-06 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US8859623B1 (en) | 2013-11-14 | 2014-10-14 | Paragon BioTeck, Inc. | Methods and compositions of stable phenylephrine formulations |
ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
CN108743587B (zh) * | 2014-01-10 | 2021-04-30 | 参天制药株式会社 | 含有吡啶基氨基乙酸化合物的药物制剂 |
CN106456584A (zh) | 2014-02-11 | 2017-02-22 | 阿拉西斯医药公司 | 用于矫正老视的药理学眼科用组合物和其施用 |
EP3302426A4 (en) * | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
US20190000808A1 (en) | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
CH711969A2 (it) | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
US10231968B2 (en) | 2016-08-01 | 2019-03-19 | David R. Hardten | Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies |
WO2018033792A2 (en) | 2016-08-19 | 2018-02-22 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
CN110114119B (zh) | 2016-10-12 | 2022-05-31 | Ps治疗有限公司 | 人工泪液、隐形眼镜和药物载体组合物及其使用方法 |
-
2019
- 2019-04-24 LT LTEPPCT/US2019/028917T patent/LT3681500T/lt unknown
- 2019-04-24 EP EP22160205.5A patent/EP4066830A1/en active Pending
- 2019-04-24 ES ES19729883T patent/ES2920803T3/es active Active
- 2019-04-24 AU AU2019261598A patent/AU2019261598B9/en active Active
- 2019-04-24 DK DK19729883.9T patent/DK3681500T3/da active
- 2019-04-24 CN CN201980037652.3A patent/CN112272558A/zh active Pending
- 2019-04-24 HU HUE19729883A patent/HUE058931T2/hu unknown
- 2019-04-24 KR KR1020207033656A patent/KR20210005134A/ko not_active IP Right Cessation
- 2019-04-24 JP JP2020559558A patent/JP6946575B2/ja active Active
- 2019-04-24 BR BR112020021845-6A patent/BR112020021845A2/pt unknown
- 2019-04-24 MX MX2020011301A patent/MX2020011301A/es unknown
- 2019-04-24 US US16/393,175 patent/US10610518B2/en active Active
- 2019-04-24 PT PT197298839T patent/PT3681500T/pt unknown
- 2019-04-24 SG SG11202010472XA patent/SG11202010472XA/en unknown
- 2019-04-24 CA CA3074618A patent/CA3074618C/en active Active
- 2019-04-24 EP EP19729883.9A patent/EP3681500B1/en active Active
- 2019-04-24 CA CA3162141A patent/CA3162141A1/en active Pending
- 2019-04-24 KR KR1020237017632A patent/KR20230079489A/ko active Search and Examination
- 2019-04-24 PL PL19729883.9T patent/PL3681500T3/pl unknown
- 2019-04-24 RS RS20220575A patent/RS63360B1/sr unknown
- 2019-04-24 HR HRP20220762TT patent/HRP20220762T1/hr unknown
- 2019-04-24 SI SI201930260T patent/SI3681500T1/sl unknown
- 2019-04-24 WO PCT/US2019/028917 patent/WO2019209955A2/en active Application Filing
-
2020
- 2020-02-14 US US16/791,039 patent/US11285134B2/en active Active
- 2020-05-21 AU AU2020203311A patent/AU2020203311A1/en not_active Abandoned
- 2020-10-20 IL IL278178A patent/IL278178A/en unknown
- 2020-10-22 CL CL2020002734A patent/CL2020002734A1/es unknown
- 2020-10-23 PH PH12020551766A patent/PH12020551766A1/en unknown
- 2020-11-24 CO CONC2020/0014563A patent/CO2020014563A2/es unknown
-
2021
- 2021-09-15 JP JP2021150116A patent/JP7470667B2/ja active Active
-
2022
- 2022-01-12 US US17/647,813 patent/US20220241245A1/en not_active Abandoned
- 2022-02-18 AU AU2022201106A patent/AU2022201106A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551766A1 (en) | Use of pilocarpine hydrochloride for the treatment of ocular conditions | |
IL282624A (en) | Methods and compositions for the treatment of sight beard, mydriasis and other disorders of the eyes | |
MX2023003124A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
MX2018014868A (es) | Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma. | |
RU2015134858A (ru) | Конфигурация линзы, не зависящей от размера зрачка, и способ для предотвращения и/или замедления прогрессирования миопии | |
EP4324454A3 (en) | Cross-linking agents and associated methods | |
MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
IL287802A (en) | Preparations and methods for the treatment of eye diseases | |
SG11202008901WA (en) | Ophthalmic compositions, and ocular uses thereof, of indigo carmine | |
EP4100014C0 (en) | COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND EYE HYPERTENSION | |
MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
TN2019000112A1 (en) | Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma | |
EP3902525A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASES | |
PT3861985T (pt) | Composições e métodos para tratar doenças oculares | |
EP3813794A4 (en) | OPHTHALMIC COMPOSITIONS AND METHODS OF TREATING EYE DISORDERS | |
MX2019011925A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
MX2018009125A (es) | Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular. | |
ZA202102872B (en) | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases | |
IL280588A (en) | Ophthalmic compositions and methods for treating eye problems and skin diseases | |
PH12021550372A1 (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
EP3914263A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES AND DISORDERS | |
EP4003223A4 (en) | CORNEAL INLAY DESIGN AND VISION CORRECTION METHODS | |
SG11202103215SA (en) | Treatment of myopia and other ocular conditions using singlet oxygen | |
MX2021012532A (es) | Composicion oftalmica desprovista de quelantes para su uso en un procedimiento para el tratamiento de un trastorno ocular. |